FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List - JD Supra
FDA removed 12 peptides from Category 2 of the 503A Bulk Drug Substances List and scheduled PCAC meetings to consider adding peptides to the list. This affects compounding pharmacies and manufacturers relying on these peptides.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Compounding pharmacies (503A), outsourcing facilities (503B), and API manufacturers supplying these peptides. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately for removal; PCAC meeting dates TBD (monitor FDA announcements).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
12 peptides are no longer on the Category 2 list, meaning they cannot be used in compounding without an FDA-approved drug product or a valid monograph. PCAC meetings may add peptides to the 503A list, which would allow their use.
Who it affects
Compounding pharmacies (503A), outsourcing facilities (503B), and API manufacturers supplying these peptides.
What you must do
Review your compounding formulas and supply chain to identify if any of the 12 peptides are used. Prepare to switch to FDA-approved alternatives or submit comments to PCAC.
Deadline
Immediately for removal; PCAC meeting dates TBD (monitor FDA announcements).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)